Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/108856
Full metadata record
DC FieldValueLanguage
dc.contributor.authorÁlvarez Larrán, Alberto-
dc.contributor.authorPereira Saavedra, Arturo-
dc.contributor.authorGuglielmelli, Paola-
dc.contributor.authorHernández Boluda, Juan Carlos-
dc.contributor.authorArellano Rodrigo, Eduardo-
dc.contributor.authorFerrer Marín, Francisca-
dc.contributor.authorSamah, Alimam-
dc.contributor.authorGriesshammer, Martin-
dc.contributor.authorKerguelen Fuentes, Ana-
dc.contributor.authorAndreasson, Bjorn-
dc.contributor.authorBurgaleta, Carmen-
dc.contributor.authorSchwarz, Jiri-
dc.contributor.authorGarcía Gutiérrez, Valentín-
dc.contributor.authorAyala, Rosa-
dc.contributor.authorBarba, Pere-
dc.contributor.authorGómez Casares, María Teresa-
dc.contributor.authorPaoli, Chiara-
dc.contributor.authorDrexler, Beatrice-
dc.contributor.authorZweegman, Sonja-
dc.contributor.authorMcMullin, Mary F.-
dc.contributor.authorSamuelsson, Jan-
dc.contributor.authorHarrison, Claire N.-
dc.contributor.authorCervantes Requena, F.-
dc.contributor.authorVannucchi, Alessandro M.-
dc.contributor.authorBesses, Carlos-
dc.date.accessioned2017-03-23T17:37:35Z-
dc.date.available2017-03-23T17:37:35Z-
dc.date.issued2016-08-01-
dc.identifier.issn0390-6078-
dc.identifier.urihttp://hdl.handle.net/2445/108856-
dc.description.abstractThe role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of lowdose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2V617F mutation) who were on antiplatelet therapy or observation only. After a follow up of 2215 person- years free from cytoreduction, 25 thrombotic and 17 bleeding episodes were recorded. In CALR-mutated patients, antiplatelet therapy did not affect the risk of thrombosis but was associated with a higher incidence of bleeding (12.9 versus 1.8 episodes per 1000 patient-years, P=0.03). In JAK2V617F-mutated patients, low-dose aspirin was associated with a reduced incidence of venous thrombosis with no effect on the risk of bleeding. Coexistence of JAK2V617F-mutation and cardiovascular risk factors increased the risk of thrombosis, even after adjusting for treatment with low-dose aspirin (incidence rate ratio: 9.8; 95% confidence interval: 2.3-42.3; P=0.02). Time free from cytoreduction was significantly shorter in CALR-mutated patients with essential thrombocythemia than in JAK2V617F-mutated ones (median time 5 years and 9.8 years, respectively; P=0.0002) and cytoreduction was usually necessary to control extreme thrombocytosis. In conclusion, in patients with low-risk, CALR-mutated essential thrombocythemia, low-dose aspirin does not reduce the risk of thrombosis and may increase the risk of bleeding.-
dc.format.extent6 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFerrata Storti Foundation-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3324/haematol.2016.146654-
dc.relation.ispartofHaematologica, 2016, vol. 101, num. 8, p. 926-931-
dc.relation.urihttps://doi.org/10.3324/haematol.2016.146654-
dc.rights(c) Ferrata Storti Foundation, 2016-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationTrombosi-
dc.subject.classificationPlaquetes sanguínies-
dc.subject.classificationMalalties hematològiques-
dc.subject.otherThrombosis-
dc.subject.otherBlood platelets-
dc.subject.otherHematologic diseases-
dc.titleAntiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec669558-
dc.date.updated2017-03-23T17:37:35Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid27175028-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
669558.pdf842.44 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.